1～3 item / All 3 items
Compound derived from slime mold having Immunosuppressive action and weight gain inhibitory action and its derivative
Previously, Ppc1, a small molecule compound derived from a cellular slime mold, was only known to inhibit the growth of cultured cells. We have demonstrated that Ppc1 and its derivatives have inhibitory and uncoupling effects on IL-2 production.
Expected application to temperature-responsive smart windows
There are known compounds that exhibit phase separation when solutes dissolved in solvents exceed a certain temperature (LCST). Poly (N-isopropylacrylamide) (PNIPAm) has been studied as a representative of these compounds, and applications to temperature-responsive smart windows have been reported. However, since the LCST of PNIPAm is constant at 31°C, a compound that can flexibly respond to the LCST depending on ambient temperature has been desired in industry. The inventors succeeded in synthesizing a new compound. This compound is characterized by the ability to control the LCST within the range of about 25~55°C by modifying a part of its structure. When applying to smart windows, most of them require a power supply because they switch between transmission and non-transmission by turning the voltage on and off. On the other hand, smart windows using this compound can be used in places without a power supply because they switch between transmission and non-transmission spontaneously according to changes in the outside temperature. Furthermore, by controlling the heat according to the degree of light transmission, it is expected to be effective against heat.
Inhibitors targeting VASH2, the highly expressed protein in cancer
Angiogenesis is known to be involved in the development and progression of cancer, diabetic nephropathy, heart failure, arteriosclerosis, and nervous system diseases. The inventors have discovered Vasohibin1 (VASH1), an angiogenesis inhibitor produced by vascular endothelial cells, Vasohibin2 (VASH2), a homolog of Vasohibin1, and Small Vasohibin Binding Protein (SVBP), which enhances their stability, and have developed new therapies based on enhancing the effects of VASH1 or inhibiting VASH2 (see "Related Inventions"). The present invention was screened from a small molecule compound library, and obtained five small molecule inhibitors that do not inhibit the binding of VASH1 and SVBP, but selectively inhibits the binding of VASH2 and SVBP. Since the patent application has not been published, the structural of the five screened compounds have not been disclosed. Please feel free to contact us as we can disclose the information after signing a non-disclosure agreement.
